Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Opus Genetics | Ocuphire Pharma

Request full access

Clinical-stage gene therapies for inherited retinal diseases

Durham, United StatesFounded 2018Biotech & Life Sciences

About Opus Genetics | Ocuphire Pharma

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on the development of gene therapies and ophthalmic treatments to address rare and debilitating inherited retinal diseases (IRDs) and other vision disorders. Formed through the all-stock acquisition of Opus Genetics by Ocuphire Pharma in October 2024, the combined entity adopted the Opus Genetics name and Nasdaq ticker symbol “IRD” to reflect its strategic focus on transformative genetic medicines for vision loss.

The company’s core mission is to restore and preserve vision by addressing the underlying genetic causes of severe retinal disorders that currently lack effective therapies. Its pipeline centers on multiple adeno-associated virus (AAV)-based gene therapy candidates, including programs targeting Leber congenital amaurosis (LCA5), BEST1-related diseases, and other mutations associated with retinitis pigmentosa and related conditions. These one-time, potentially durable treatments aim to deliver healthy copies of defective genes directly to retinal cells, offering hope for patients with historically untreatable forms of blindness.

In addition to its gene therapy portfolio, Opus Genetics continues to develop phentolamine ophthalmic solution 0.75%, an approved small-molecule therapy originally advanced by Ocuphire, which is being evaluated in Phase 3 clinical trials for conditions such as presbyopia and low-light vision disturbances following keratorefractive surgery. The company also collaborates with strategic partners to further small-molecule and biologic ophthalmic programs where appropriate.

Opus Genetics serves patients, clinicians, and the broader retinal disease community worldwide. Its value proposition lies in combining world-class gene therapy innovation—rooted in scientific expertise and supported by leading researchers and clinicians—with clinical development experience and capital resources to accelerate regulatory milestones and broaden patient access. The company’s work occurs within a rapidly evolving biotechnology landscape in which genetic medicines are increasingly recognized for their potential to deliver durable, targeted treatments for conditions once considered untreatable.

Headquartered in Research Triangle Park/Durham, North Carolina, Opus Genetics is led by a seasoned management team and board with deep experience in ophthalmology, gene therapy, and translational science. The company positions itself at the intersection of cutting-edge biotechnology and patient-centric innovation, addressing substantial unmet medical needs in rare ophthalmic diseases while pursuing broader applications that could impact millions of patients globally.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2018
Headquarters
Durham, United States
Listing
IPO 2004
Employees
44
Open positions
3
Dealroom signal
94.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Seal of Excellence EC, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Oct 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Apr 2026 $5M — Oberland Capital ↗
GRANTOther financing Apr 2026 $35M — Oberland Capital ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 $15M +4.7% −$37M -245.8%
2025 $14M +29.1% −$37M -257.5%
2024 $11M -42.3% −$30M -269.2%
2023 $19M -52.2% −$8.7M -45.8%
2022 $40M +6665.7% $18M 45.7%
2021 $589K — −$23M -3880.8%
2020 — — −$9.4M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Opus Genetics | Ocuphire Pharma website traffic

Latest recorded traffic for Opus Genetics | Ocuphire Pharma is 7.1K monthly website visits, down 16.5% over the last three months. Opus Genetics | Ocuphire Pharma's team grew 46.7% over the past year.

Latest monthly visits7.1K 3-month web change-16.5% 1-year team growth+46.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Opus Genetics | Ocuphire Pharma in the Durham ecosystem

Live from Dealroom

The Opus Genetics | Ocuphire Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • National Eye Institute
  • Retinal Degeneration Fund

Series B and later11 investors entered at this stage

  • Michigan Angel Fund
  • Blue Water Angels
  • BELLE Capital
  • Grand Angels
  • Ann Arbor Angels
  • Perceptive Advisors
  • Nantahala Capital Management
  • George Magrath
  • Cam Gallagher
  • Balyasny Asset Management
  • Oberland Capital

Other known investors8 additional known investors

  • Adage Capital
  • Marshall Wace
  • Trails Edge Capital Partners
  • Altium Capital Management
  • Belle Fund
  • Biosciences Research and Commercialization Center
  • ID Ventures
  • Michigan Capital Network
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Durham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Opus Genetics | Ocuphire Pharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Opus Genetics | Ocuphire Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.